{"editorial":{"content_id":"f53f612a-288e-43c7-b423-655ed32885d0","slug":"prati-donaduzzi-10mg-25mg-20261109-6f58fd","content_type":"news","title":"Prati-Donaduzzi 推出恩格列净仿制药，10mg 与 25mg 两种规格","summary":"巴西制药公司 Prati-Donaduzzi 推出恩格列净仿制药，用于成人 2 型糖尿病治疗，有 10 毫克和 25 毫克两种规格。","body":"巴西制药公司 Prati-Donaduzzi 扩展其慢性病治疗产品组合，推出恩格列净（empagliflozina）仿制药，适用于成人 2 型糖尿病患者。该产品为处方药，提供 10 毫克和 25 毫克两种规格，每盒 30 片。\n\n据原文介绍，恩格列净除用于 2 型糖尿病患者的血糖控制外，还具有与心力衰竭和慢性肾病相关的适应症。该公司产品组合中已包含其他糖尿病治疗药物，如二甲双胍、格列美脲和格列本脲。\n\n恩格列净通过抑制肾脏对葡萄糖的重吸收发挥作用，从而增加葡萄糖经尿液排出。该公司医疗及处方咨询顾问 Larissy Degani 医生表示：“在某些患者群体中，该药可降低心血管死亡、心力衰竭住院和慢性肾病进展的风险。”\n\n原文还标注了产品注册号 M.S.: 25351.109346/2025-80 08/2036，并注明分销采用公司自有系统。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["企业动态","行业趋势","br-health"],"content_level":"编辑整理","event_type":"公司动态","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-11-09T17:03:09.976Z","display_date":"2026-11-09","source_published_at":null,"source_url":"https://panoramafarmaceutico.com.br/prati-donaduzzi-lanca-empagliflozina-generica/","source_name":"Panorama Farmacêutico","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":[],"opportunity_flags":["market_entry_opportunity"],"trend_signals":["generic_drug_market_expansion","chronic_disease_market_growth"]},"intelligence":{"intel_id":"603a4b41-d549-4211-b42a-083697a8d0b2","version":1,"event_type":"产品上线","event_date":null,"main_entities":[{"name":"Prati-Donaduzzi","role":"推出恩格列净仿制药的巴西制药公司","type":"company","country":"巴西","normalized_name":null},{"name":"恩格列净仿制药","role":"新上市的成人2型糖尿病治疗处方药","type":"product","country":"巴西","normalized_name":null},{"name":"Larissy Degani","role":"Prati-Donaduzzi医疗及处方咨询顾问","type":"person","country":"巴西","normalized_name":null}],"main_action":"Prati-Donaduzzi推出恩格列净仿制药，规格10mg和25mg。","key_numbers":[{"unit":"mg","label":"规格1","value":"10"},{"unit":"mg","label":"规格2","value":"25"},{"unit":"片","label":"每盒片数","value":"30"},{"unit":"","label":"产品注册号","value":"M.S. 25351.109346/2025-80 08/2036"}],"facts":[{"verified":false,"statement":"Prati-Donaduzzi 推出恩格列净（empagliflozina）仿制药，适用于成人2型糖尿病患者。","source_excerpt":null},{"verified":false,"statement":"该产品为处方药，提供10毫克和25毫克两种规格，每盒30片。","source_excerpt":null},{"verified":false,"statement":"恩格列净除用于2型糖尿病患者血糖控制外，还具有与心力衰竭和慢性肾病相关的适应症。","source_excerpt":null},{"verified":false,"statement":"Prati-Donaduzzi 产品组合中已包含二甲双胍、格列美脲和格列本脲。","source_excerpt":null},{"verified":false,"statement":"产品注册号为 M.S. 25351.109346/2025-80 08/2036，分销采用公司自有系统。","source_excerpt":null},{"verified":false,"statement":"Larissy Degani 医生表示，在某些患者群体中，该药可降低心血管死亡、心力衰竭住院和慢性肾病进展的风险。","source_excerpt":null}],"assessments":[{"statement":"此次上市扩充了 Prati-Donaduzzi 的慢病治疗产品组合，并可能加剧巴西恩格列净仿制药市场竞争。","confidence":"medium","basis_fact_index":null},{"statement":"仿制药上市可能提升巴西2型糖尿病及心肾适应症患者对恩格列净的可及性。","confidence":"medium","basis_fact_index":null},{"statement":"注册号标注有效至2036年，表明该产品具备较长期商业化注册基础。","confidence":"medium","basis_fact_index":null},{"statement":"采用公司自有分销系统表明 Prati-Donaduzzi 对渠道控制较强，但第三方分销合作空间可能有限。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"both","priority":"high","description":"监测ANVISA注册与说明书信息，确认心力衰竭和慢性肾病适应症范围。"},{"target":"both","priority":"normal","description":"跟踪巴西市场定价、医保报销及医院/零售渠道覆盖情况。"},{"target":"user","priority":"normal","description":"核实正式上市日期及公司自有分销系统的合作政策。"}],"affected_audience":["巴西成人2型糖尿病患者","心力衰竭患者","慢性肾病患者","巴西处方医生","仿制药竞争对手","药品分销商"],"risk_flags":[],"opportunity_flags":["market_entry_opportunity"],"trend_signals":["generic_drug_market_expansion","chronic_disease_market_growth"],"follow_up_needed":true,"follow_up_questions":["该产品在巴西的正式上市日期和医院/零售渠道覆盖情况如何？","ANVISA注册号对应的适应症标签是否包含心力衰竭和慢性肾病？","产品定价、医保报销及与原研药和其他仿制药的价格差异如何？","M.S. 25351.109346/2025-80 08/2036 的具体注册状态和有效期是什么？","公司自有分销系统是否向第三方分销商或合作伙伴开放？"],"related_topics":["恩格列净","仿制药","2型糖尿病","心力衰竭","慢性肾病","巴西制药市场","Prati-Donaduzzi","ANVISA"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-11-09T17:03:33.565Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/prati-donaduzzi-10mg-25mg-20261109-6f58fd","api_url":"https://chinabrazilinsight.com/api/public/content/prati-donaduzzi-10mg-25mg-20261109-6f58fd","markdown_url":"https://chinabrazilinsight.com/api/public/content/prati-donaduzzi-10mg-25mg-20261109-6f58fd?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/prati-donaduzzi-10mg-25mg-20261109-6f58fd?view=json","last_updated":"2026-11-09T17:03:33.698Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}